Opportunity Information: Apply for RFA CA 12 012
Apply for RFA CA 12 012
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jul 23, 2012 and posted on Jul 23, 2012.
- Applicants must submit their applications by Jan 15, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity RFA-CA-12-012 is a National Institutes of Health (NIH), National Cancer Institute (NCI) cooperative agreement (U10) aimed at creating Network Group Integrated Translational Science Centers within the NCI National Clinical Trials Network (NCTN). In plain terms, NCI is looking for institutions that can serve as dedicated translational science hubs for NCTN network groups, helping move discoveries from the laboratory and other research settings into well-designed clinical trials, and then using what is learned from patients in those trials to refine and accelerate future research. The overarching purpose is to strengthen the translational backbone of NCTN so that large, multi-institution cancer clinical trials are not only operationally strong, but also biologically and scientifically integrated in a way that improves treatment development and evaluation for both adult and pediatric cancer patients.
This FOA sits inside a larger NCTN structure that is intentionally broken into six coordinated components, each supported under its own separate funding announcement. Those components are: Network Group Operations Centers, Network Group Statistics and Data Management Centers, Network Group Integrated Translational Science Centers (the focus of this announcement), Lead Academic Participating Site Centers, Network Radiotherapy and Imaging Core Services Centers, and a Canadian Collaborating Clinical Trials Network. The Integrated Translational Science Centers are meant to plug into that broader system by ensuring that clinical trials conducted by the network groups are paired with high-quality translational research capabilities, including the kinds of laboratory, biospecimen, and correlative science functions needed to understand how and why therapies work (or fail), identify biomarkers, and improve patient selection, monitoring, and outcome interpretation.
The scientific and clinical context emphasized in the announcement is the NCTN mission of developing and running state-of-the-art cancer treatment and advanced imaging trials, with particular focus on large, definitive, multi-institutional studies that evaluate new therapies and related clinical approaches. The translational center concept is important here because modern oncology trials increasingly depend on integrated biology: tissue and blood-based studies, molecular characterization, biomarker validation, and other correlative analyses that can explain response and resistance, guide future trial design, and support precision medicine approaches. While the notice provided does not list detailed task requirements, the intent is clear that awardees are expected to function as network-level resources that integrate translational science into the lifecycle of NCTN trials rather than treating correlative studies as an afterthought.
From an administrative standpoint, this is a discretionary grant mechanism using a cooperative agreement (U10). A cooperative agreement generally indicates substantial federal involvement, meaning NCI will likely have an active role in coordinating, guiding, or partnering in programmatic aspects of the funded activities compared with a standard research project grant. The activity categories tied to the CFDA listings include cancer detection and diagnosis research (93.394) and cancer treatment research (93.395), reflecting the expectation that translational work will span both understanding disease and improving therapeutic strategies. The FOA specifies there is no cost sharing or matching requirement.
In terms of funding scale and timing, the estimated total funding amount shown is $4,000,000, with the opportunity originally posted on July 23, 2012. The original and current closing date listed is January 15, 2013, and the archive date is February 15, 2013, which indicates the competition is historical rather than currently open. Even so, the structure is useful as a reference point for how NCI organized translational science support within the NCTN framework during that period.
Eligibility is broad across U.S.-based organizational types that can credibly operate at the level required for national network clinical trial support. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, for-profit organizations other than small businesses, and nonprofit organizations with or without 501(c)(3) status (with distinctions noted for those that are not institutions of higher education). The eligibility language also explicitly calls out categories of “other eligible applicants,” including Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), tribally controlled colleges and universities (TCCUs), and regional organizations. At the same time, non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply; however, “foreign components,” as defined in the NIH Grants Policy Statement, are allowed, which typically means discrete project components carried out outside the U.S. may be permissible under NIH rules when well-justified and compliant.
Finally, the announcement provides a link to the full FOA text on the NIH grants site (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-012.html) and offers NIH Office of Extramural Research (OER) webmaster contact information for technical access or linking issues. The key takeaway is that this opportunity was designed to build and formalize translational science capacity embedded within NCTN network groups so that large-scale cancer clinical trials could be more scientifically informative, biologically grounded, and better positioned to advance new treatments and advanced imaging approaches efficiently across many institutions.
FAQs: RFA-CA-12-012 (NCI/NIH) Network Group Integrated Translational Science Centers (U10)
What is RFA-CA-12-012?
RFA-CA-12-012 is a National Institutes of Health (NIH), National Cancer Institute (NCI) funding opportunity for a cooperative agreement (U10) to create Network Group Integrated Translational Science Centers within the NCI National Clinical Trials Network (NCTN).
What is the main goal of this funding opportunity?
The main goal is to strengthen the translational science backbone of the NCTN by establishing dedicated translational science hubs for NCTN network groups. These hubs are intended to help move discoveries from laboratory and other research settings into well-designed clinical trials, and then use insights from patients in those trials to refine and accelerate future research.
In plain terms, what would an awardee be expected to do?
Awardees are expected to function as network-level translational science resources that integrate biology and correlative science into NCTN clinical trials across the trial lifecycle, rather than treating translational studies as an add-on.
What is an "Integrated Translational Science Center" in the NCTN context?
It is a dedicated center that supports NCTN network group trials by providing high-quality translational research capabilities such as laboratory support, biospecimen-related functions, and correlative science to understand treatment response and resistance, identify biomarkers, improve patient selection and monitoring, and strengthen interpretation of clinical outcomes.
How does this FOA fit within the broader NCTN structure?
This FOA is one of six coordinated NCTN components, each supported under separate funding announcements. The six components are: Network Group Operations Centers, Network Group Statistics and Data Management Centers, Network Group Integrated Translational Science Centers (this FOA), Lead Academic Participating Site Centers, Network Radiotherapy and Imaging Core Services Centers, and a Canadian Collaborating Clinical Trials Network.
What kinds of clinical trials are emphasized in this opportunity?
The opportunity emphasizes state-of-the-art cancer treatment and advanced imaging trials, with a particular focus on large, definitive, multi-institutional studies that evaluate new therapies and related clinical approaches for both adult and pediatric cancer patients.
Why is translational science highlighted as important for these trials?
Modern oncology trials increasingly depend on integrated biology, including tissue- and blood-based studies, molecular characterization, biomarker validation, and other correlative analyses. These elements can help explain response and resistance, guide future trial design, and support precision medicine approaches.
What funding mechanism is used for this opportunity?
This opportunity uses a cooperative agreement mechanism (U10).
What does a cooperative agreement (U10) imply about NCI involvement?
A cooperative agreement generally indicates substantial federal involvement. Based on the description provided, NCI would likely have an active role in coordinating, guiding, or partnering in programmatic aspects of the funded activities compared with a standard research project grant.
Is this a discretionary grant?
Yes. The announcement describes it as a discretionary grant mechanism.
Is cost sharing or matching required?
No. The FOA specifies there is no cost sharing or matching requirement.
What is the estimated total funding amount?
The estimated total funding amount shown is $4,000,000.
When was the opportunity posted?
The opportunity was originally posted on July 23, 2012.
What was the application closing date?
The original and current closing date listed is January 15, 2013.
Is this funding opportunity currently open?
No. The archive date is February 15, 2013, indicating the competition is historical rather than currently open.
Which CFDA program areas are associated with this FOA?
The activity categories tied to the CFDA listings include cancer detection and diagnosis research (93.394) and cancer treatment research (93.395).
What does the CFDA pairing suggest about the scope of translational work?
It reflects an expectation that the translational work will span both understanding disease (detection/diagnosis research) and improving therapeutic strategies (treatment research).
Who is eligible to apply?
Eligible applicants include U.S.-based public and state-controlled institutions of higher education, private institutions of higher education, for-profit organizations other than small businesses, and nonprofit organizations with or without 501(c)(3) status (with distinctions noted for those that are not institutions of higher education).
Are specific institution types explicitly called out as eligible?
Yes. The eligibility language explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), tribally controlled colleges and universities (TCCUs), and regional organizations under “other eligible applicants.”
Are non-U.S. (foreign) institutions eligible to apply?
No. Non-U.S. (foreign) institutions are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible to apply?
No. Non-U.S. components of U.S. organizations are also not eligible to apply.
Are "foreign components" allowed under this FOA?
Yes. “Foreign components,” as defined in the NIH Grants Policy Statement, are allowed. This typically means discrete project components carried out outside the U.S. may be permissible under NIH rules when well-justified and compliant.
What role do these Translational Science Centers play relative to NCTN network groups?
They are intended to serve as dedicated translational science hubs that plug into the broader NCTN system and support network group trials with integrated laboratory and correlative science capabilities.
What kinds of translational capabilities are implied by the FOA description?
The description highlights laboratory support, biospecimen-related functions, tissue and blood-based studies, molecular characterization, biomarker validation, and correlative analyses to understand mechanisms of response and resistance and to improve trial design and interpretation.
Where can the full FOA text be found?
The full FOA text is linked on the NIH grants site at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-012.html.
Is there a contact for technical issues accessing the FOA link?
Yes. The announcement notes NIH Office of Extramural Research (OER) webmaster contact information for technical access or linking issues.
What is the key takeaway of this historical opportunity?
It was designed to build and formalize translational science capacity embedded within NCTN network groups so that large-scale cancer clinical trials could be more scientifically informative, biologically grounded, and better positioned to advance new treatments and advanced imaging approaches efficiently across many institutions.
Browse more opportunities from the same category: Education Health
Next opportunity: NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10)
Previous opportunity: NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 12 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 12 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 023 Funding Number: RFA CA 12 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R01) Apply for RFA DA 13 010 Funding Number: RFA DA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R21) Apply for RFA DA 13 011 Funding Number: RFA DA 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R21 Apply for PA 12 274 Funding Number: PA 12 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R01 Apply for PA 12 275 Funding Number: PA 12 275 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad Program Apply for DRAFT APS ASHA 12 000001 Funding Number: DRAFT APS ASHA 12 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) Apply for PA 12 280 Funding Number: PA 12 280 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01) Apply for PA 12 281 Funding Number: PA 12 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS Science Track Award for Research Transition (R03) Apply for PA 12 282 Funding Number: PA 12 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revisions for Early Stage Development of Informatics Technology (R01) Apply for PAR 12 286 Funding Number: PAR 12 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 12 287 Funding Number: PAR 12 287 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Early Stage Development of Informatics Technology (U01) Apply for PAR 12 288 Funding Number: PAR 12 288 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Revisions for Early Stage Development of Informatics Technology (U01) Apply for PAR 12 289 Funding Number: PAR 12 289 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 12 290 Funding Number: PAR 12 290 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Research Answers to NCIs Provocative Questions Group A (R01) Apply for RFA CA 12 015 Funding Number: RFA CA 12 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group A (R21) Apply for RFA CA 12 016 Funding Number: RFA CA 12 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group B (R01) Apply for RFA CA 12 017 Funding Number: RFA CA 12 017 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group B (R21) Apply for RFA CA 12 018 Funding Number: RFA CA 12 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 12 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.